Brief: Revive Provides Update On Phase 3 Clinical Trial For Bucillamine In COVID-19
29/03/2022 13:48
March 29 (Reuters) - Revive Therapeutics Ltd RVV.CD :
* REVIVE THERAPEUTICS PROVIDES UPDATE ON PHASE 3 CLINICAL
TRIAL
FOR BUCILLAMINE IN COVID-19
* REVIVE THERAPEUTICS LTD - EXPECTED TO SEEK DSMB APPROVAL
TO
PROCEED WITH EUA APPLICATION TO FDA IN Q2-2022
* REVIVE THERAPEUTICS - NOT MAKING ANY EXPRESS/IMPLIED
CLAIMS THAT
ITS PRODUCT HAS ABILITY TO ELIMINATE OR CURE COVID-19 AT THIS
TIME
* REVIVE THERAPEUTICS LTD - PREPARING ITS REGULATORY PACKAGE
FOR
SUBMISSION TO FDA AND INTERNATIONAL REGULATORY AUTHORITIES FOR
DRUG APPROVALS
Source text for Eikon: ID:nGNXbLxB24
Further company coverage: RVV.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Revive Therapeutics
See all newsBrief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Announces Closing Of Second Tranche Of Private Placement
Brief: Revive Therapeutics Nears Completion Of Key Nerve Agent Countermeasure Study With Canadian Department Of National Defence
Brief: Revive Therapeutics Provides Update On Research Study Evaluating Bucillamine For Nerve Agent Exposure